NCT00845949

Brief Summary

Rheumatoid arthritis is a common chronic destructive arthritis. Major pathology change in rheumatoid arthritis is synovium hyperplasia with bone and cartilage erosion. Infiltrates in synovial tissue included type one and type two synoviocytes, B cells, T cells and fibroblasts. These cells will release many cytokines and chemokines, which will induce expression of adhesion molecules, release of variable enzyme from fibroblast and osteoclast and result in bone erosion. Recent study revealed that fibroblast-like synoviocytes (FLS) have some role in pathogenesis of rheumatoid arthritis.We believed CXCL12/CXCR4 ligand/receptor pair is important in chronicity of rheumatoid arthritis. CXCL12 polymorphism is studied in many disease. There is no related CXCL12 polymorphism study in rheumatoid arthritis. Our study intended to clarify the relationship between pathology, serology factor, CXCL12 polymorphism in rheumatoid arthritis in hope that new direction of therapy will be elucidated.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2006

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

March 3, 2008

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
9 months until next milestone

First Posted

Study publicly available on registry

February 18, 2009

Completed
Last Updated

May 21, 2012

Status Verified

May 1, 2012

Enrollment Period

1.6 years

First QC Date

March 3, 2008

Last Update Submit

May 18, 2012

Conditions

Rheumatoid Arthritis

Keywords

chemokines synovium

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Synovial tissue from patient with rheumatoid arthritis who underwent total knee replacement surgery after informed consent.

You may qualify if:

  • patients with rheumatoid arthritis fulfills ACR 1987 classification criteria for rheumatoid arthritis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Allergy, Autoimmunity and Rheuamtology, Department of Internal Medicine, Far Eastern Memorial Hospital

Banqiao District, 220, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Synovial tissue

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Chien-Sheng Wu

    Division of Allergy, Autimmunity and Rheumatology, Department of Internal Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, Division of Rheumatology

Study Record Dates

First Submitted

March 3, 2008

First Posted

February 18, 2009

Study Start

November 1, 2006

Primary Completion

June 1, 2008

Study Completion

June 1, 2008

Last Updated

May 21, 2012

Record last verified: 2012-05

Locations

TW(1)